MITOCARE
Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease
| Coordinatore | TROPHOS SA
Organization address
address: PARC SCIENTIFIQUE LUMINY CASE 931 contact info |
| Nazionalità Coordinatore | France [FR] |
| Sito del progetto | http://www.mitocare.eu |
| Totale costo | 8˙192˙211 € |
| EC contributo | 5˙990˙959 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2013-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TROPHOS SA
Organization address
address: PARC SCIENTIFIQUE LUMINY CASE 931 contact info |
FR (MARSEILLE CEDEX 9) | coordinator | 2˙199˙952.00 |
| 2 |
FIRALIS S.A.S.
Organization address
address: Rue du Fort contact info |
FR (Huningue) | participant | 778˙321.00 |
| 3 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 536˙624.00 |
| 4 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 413˙120.00 |
| 5 |
IMACOR AB
Organization address
address: REKTORSVAGEN 16 contact info |
SE (LUND) | participant | 299˙460.00 |
| 6 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 278˙988.00 |
| 7 |
UNIVERSITY OF BRISTOL
Organization address
address: TYNDALL AVENUE SENATE HOUSE contact info |
UK (BRISTOL) | participant | 272˙064.00 |
| 8 |
REGION NORDJYLLAND (NORTH DENMARK REGION)
Organization address
address: Niels Bohrs Vej 30 contact info |
DK (AALBORG) | participant | 258˙276.00 |
| 9 |
UNIVERSITETET I BERGEN
Organization address
address: Museplassen 1 contact info |
NO (BERGEN) | participant | 212˙512.00 |
| 10 |
ODENSE UNIVERSITETSHOSPITAL
Organization address
address: Sdr. Boulevard 29 contact info |
DK (ODENSE) | participant | 206˙608.00 |
| 11 |
OSLO UNIVERSITETSSYKEHUS HF
Organization address
address: FORSKNINGSVEIEN 2B contact info |
NO (OSLO) | participant | 201˙530.00 |
| 12 |
MOBILE HEALTH SAS
Organization address
address: Avenue KLEBER 112 contact info |
FR (PARIS) | participant | 113˙525.89 |
| 13 |
HELSE STAVANGER HF
Organization address
address: GERD RAGNA BLOCH THORSENS GATE 8 contact info |
NO (Stavanger) | participant | 101˙052.00 |
| 14 |
CENTRE HOSPITALIER REGIONAL DE MARS EILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE
Organization address
address: RUE BROCHIER 80 contact info |
FR (MARSEILLE CEDEX 20) | participant | 73˙674.00 |
| 15 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 35˙184.00 |
| 16 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 10˙068.11 |
| 17 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Current interventional treatment of acute myocardial infarction (AMI) focused on re-establishing cardiac reperfusion has significantly improved clinical outcome by reducing infarct size and mortality due to cardiac ischemia.It is now recognized that events triggered at reperfusion also result in cell death and may account for as much as 50% of the infarct volume, this being termed ischemia-reperfusion injury (IRI). Mitochondrial permeability transition pore (mPTP) opening appears to be a responsible for IRI and a recent small clinical trial with cyclosporine A shows that it is a feasible target for the development of new therapies to treat it. Since total infarct size is a major determinant of a patients risk to develop heart failure, treating IRI is expected to further reduce morbidity, mortality and the need for regenerative medicine following cardiac ischemia. By harnessing a multi-disciplinary consortium of clinical and basic scientists along with four SMEs, MitoCare brings state-of-the art expertise together to 1) better understand IRI pathophysiology and factors directly or indirectly influencing patient’s recovery or response to treatment; 2) investigate the translational usefulness of preclinical models; and 3) compare selected treatments. These objectives will be reached through the following work plan: A) a medium-scale phase II clinical study will evaluate the efficacy of a novel complementary therapy to PCI, the new mPTP modulator TRO40303, while at the same time 1) perform extensive sampling from subjects in the study for analysis of standard and emerging biomarkers; 2) identify confounding factors influencing patients’ outcomes. B) Parallel investigations in preclinical in vitro and in vivo AMI models. C) Statistical analysis of data from clinical and preclinical studies, to identify better diagnostic and prognostic endpoints in man and assess predictive utility of preclinical models.'
Introduzione (Teaser)
Every year, millions of cardiac reperfusion procedures are performed worldwide for treatment of heart tissue death or myocardial infarction (MI). The serious side-effects of this procedure have prompted scientists to look for alternative approaches that provide cardiac recovery while reducing the infarct size.